SCHEMBL6601301

SCHEMBL6601301

CCCC(=O)Oc1cccc2c1[nH]c1ccccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP14 Q460N5 7/20 0.51
ERAP1 Q9NZ08 1/20 0.46
KIF11 P52732 2/20 0.45
KDM4E B2RXH2 3/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
RECQL P46063 1/20 0.43
PDGFRB P09619 1/20 0.43
PDGFRA P16234 1/20 0.43
GABRP O00591 2/20 0.42
GABRD O14764 2/20 0.42
GABRA1 P14867 2/20 0.42
GABRB1 P18505 2/20 0.42
GABRG2 P18507 2/20 0.42
GABRB3 P28472 2/20 0.42
GABRA5 P31644 2/20 0.42
GABRA3 P34903 2/20 0.42
GABRA2 P47869 2/20 0.42
GABRB2 P47870 2/20 0.42
GABRA4 P48169 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9397133 0.91 POLM (0.50) PARP14ERAP1KDM4EMEN1KMT2A
SCHEMBL27864646 0.91 POLM (0.50) PARP14ERAP1KDM4EMEN1KMT2A
SCHEMBL9398516 0.91 POLM (0.50) PARP14ERAP1KDM4EMEN1KMT2A
SCHEMBL3924071 0.90 PARP14 (0.50) PARP14ERAP1KIF11KDM4EMEN1
SCHEMBL29001995 0.85 KIF11 (0.44) PARP14ERAP1KIF11GABRPGABRD
SCHEMBL31031443 0.85 POLM (0.55) PARP14KDM4EMEN1KMT2ARECQL
SCHEMBL11584101 0.84 EGFR (0.46) PARP14ERAP1KIF11KDM4EGABRP
SCHEMBL27747315 0.83 ERAP1 (0.46) PARP14ERAP1KIF11KDM4EMEN1
SCHEMBL2429422 0.82 PARP14 (0.51) PARP14KIF11KDM4EMAPTJAK2
SCHEMBL4786156 0.82 SLC22A6 (0.55) PARP14KIF11KDM4EMAPTJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110035749-A FABP4 as a therapeutic target in skin disorders 蒂库尔有限公司 2019-07-19 CN claimed
CN-106659765-A Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer 德玛医药 2017-05-10 CN claimed
CN-118103357-A FABP4/5 inhibitors, methods of use and methods of preparation 塞洛拉姆股份有限公司 2024-05-28 CN disclosed
CN-115998871-A FABP4 as therapeutic target in dermatological diseases 蒂库尔有限公司 2023-04-25 CN disclosed
CN-106659765-B Use of dianhydrogalactitol and analogs or derivatives thereof for treating non-small cell lung cancer and ovarian cancer 德玛医药 2021-08-13 CN disclosed
CN-110035749-A FABP4 as a therapeutic target in skin disorders 蒂库尔有限公司 2019-07-19 CN disclosed
CN-106659765-A Use of dianhydrogalactitol and analogs or derivatives thereof to treat non-small-cell carcinoma of the lung and ovarian cancer 德玛医药 2017-05-10 CN disclosed
EP-0923569-B1 BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS WARNER LAMBERT CO (US) 2004-11-17 EP disclosed
US-6020366-A Butyric acid matrix metalloproteinase inhibitors WARNER-LAMBERT COMPANY (US) 2000-02-01 US disclosed
EP-0923569-A1 BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1999-06-23 EP disclosed
WO-1998006711-A1 BUTYRIC ACID MATRIX METALLOPROTEINASE INHIBITORS WARNER-LAMBERT COMPANY (US) 1998-02-19 WO disclosed